News
TOURMALINE BIO ($TRML) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.86 per share, beating estimates of -$0.89 by $0 ...
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Tourmaline Bio (TRML – Research Report). The company’s shares closed yesterday at $12.94.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback